Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653559 | 0.89 | IDO1 (0.40) | FGFR1SRCHPGDALDH1A1NPC1 | |
| SCHEMBL2655343 | 0.81 | TP53 (0.44) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2655889 | 0.80 | HPGD (0.32) | FGFR1SRCHPGDALDH1A1NPC1 | |
| SCHEMBL2655083 | 0.78 | HPGD (0.38) | FGFR1SRCHPGDALDH1A1NPC1 | |
| SCHEMBL2654543 | 0.77 | HPGD (0.37) | FGFR1SRCHPGDALDH1A1NPC1 | |
| SCHEMBL2656192 | 0.74 | IDO1 (0.49) | FGFR1HPGDALDH1A1NPC1RAB9A | |
| SCHEMBL2654246 | 0.73 | FGFR1 (0.61) | FGFR1HPGDALDH1A1 | |
| SCHEMBL2653551 | 0.73 | FGFR1 (0.46) | FGFR1SRCHPGD | |
| SCHEMBL7830383 | 0.72 | KDR (0.45) | FGFR1HPGDALDH1A1 | |
| SCHEMBL7832246 | 0.71 | ALDH1A1 (0.42) | FGFR1HPGDALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | FGFR1 3374/4885SRC 3558/4885HPGD 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.